PCSK9 inhibition in heart failure PCSK9 and diabetes risk Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors EPIC-STEMI: Early alirocumab shows benefit in STEMI patients

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis Real-world use of PCSK9 inhibitors: latest insights ORION-3: 4-year data with inclisiran How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors

Most viewed

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis

Hot Topics

17th Virtual Closed Scientific Expert Meeting of the Editorial Board

Keynote lecture: Dr Albert Wiegman discusses the role of cIMT and CTCA in managing children with FH.

Watch now

News from PCSK9 research:What is the role of PCSK9 in insulin secretion? Dr Wilfried Le Goff discusses the latest data linking PCSK9 with pancreatic beta cell biology.

Watch now

From the Editors

Reducing residual risk: Are cholesterol crystals the next target?

Prof John Chapman Pitié-Salpetrière University Hospital, INSERM, Paris France discusses how cholesterol crystals play a crucial role in atherothrombosis, and potential therapeutic options.